KRAS and cholangiocarcinoma: Recently, our group reported that KRAS alteration and chromosomal instability were associated with resistance to PD-1/PD-L1 blockade immunotherapy, whereas high intratumoral tumor-infiltrating lymphocyte density was associated with a favorable immunotherapy response in patients with CCA (35).